CTT Pharmaceutical Holdings, Inc. (CTTH) stock
Close on Oct 16, 2026Market cap $1.26MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2015
Valuation
- Market cap
- $1.26M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.70
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$1.67M
- EPS, diluted
- -$0.03
- Book value per share
- $0.03
- Diluted shares
- 21M
Trading
- Previous close
- $0.06
- Open
- $0.05
- Day's range
- $0.05 – $0.06
- Volume
- 2,999
- Average volume (20 days)
- 24,006
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTTH | S&P 500 | Difference | CTTH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.0% | +1.5% | +21.5 pts | ||
| 3 months | -3.4% | +1.9% | −5.4 pts | ||
| Year to date | -2.0% | +12.8% | −14.8 pts | ||
| 1 year | -29.3% | +16.8% | −46.1 pts | ||
| 3 years | +1800.0% | +81.5% | +1718.5 pts | +166.8% | +22.0% |
| 5 years | +24.8% | +83.0% | −58.2 pts | +4.5% | +12.8% |
| 10 years | +17.8% | +319.4% | −301.6 pts | +1.7% | +15.4% |
Fifteen years at a glance
Fiscal years 2000 to 2014 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases CTT Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K
About CTT Pharmaceutical
Pharmaceutical Preparations
Mindesta Inc. is a development-stage pharmaceutical technology company focused on drug delivery systems. Operating through its wholly owned subsidiary, CTT Pharmaceuticals, Inc., the company specializes in fast-dissolving oral thin wafers designed to carry pharmaceutical agents. Its primary focus is creating cannabis-infused wafers containing natural or synthetic cannabinoids for pain management and treating the side effects of cancer therapy, offering an alternative to smoking or swallowing pills. The company targets patients requiring fast-acting relief, such as individuals suffering from acute or persistent pain, as well as pediatric and geriatric patients who experience difficulty swallowing conventional medications.
Company profile, executives and historyCTT Pharmaceutical stock: common questions
What is CTT Pharmaceutical's stock price?
CTTH closed at $0.06 on Oct 16, 2026, down 0.17% on the day.
What is CTT Pharmaceutical's market cap?
CTT Pharmaceutical was worth $1.26M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is CTTH's P/E ratio?
CTT Pharmaceutical lost money over the twelve months to Sep 30, 2015 (diluted EPS -$0.03), so it has no meaningful P/E ratio.
Does CTT Pharmaceutical pay a dividend?
No. CTT Pharmaceutical has not paid a cash dividend over the last twelve months.
How has CTTH stock performed over the past year?
Including dividends, CTTH returned -29.3% over the past year, against +16.8% for the S&P 500.
Who are CTT Pharmaceutical's competitors?
Companies most similar to CTT Pharmaceutical by business, industry and size include CNBX, SMNR, MTRI, GSAC, DWTX.
See a number that looks wrong?